In a deal which had been anticipated, Teva Pharmaceutical Industries (NYSE: TEVA) announced it would buy Allergan Generics in a transaction valued at $40.5 billion. According to a press release issued by…
Douglas A. McIntyre Teva could be about to enter the largest generic market by prescription in the world, which may tip the scales in its favor when it comes to wooing Mylan shareholders.
The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short interest decreased.
Tuesday's top analyst upgrades, downgrades and initiations include Electronic Arts, Fitbit, Shake Shack, Tesla Motors, Teva Pharmaceutical Industries and Wingstop.
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) is trying to transform itself by making its generics business even larger if it can pull off its desire to acquire Mylan N.V. (NASDAQ: MYL). The…
The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short interest is mixed.
Back in November of 2010, 24/7 Wall St. first issued a list of stocks to own for the next decade. Even long-term investors need to assess their portfolios from time to time.
The April 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
ThinkstockThe trend towards generic drugs is nothing new. It does not matter if a drug has billions of dollars in annual sales or not, when they go off patent generics can enter…
Wednesday's top analyst upgrades, downgrades and initiations include Altera, Amazon.com, Chipotle Mexican Grill, Halliburton, MGIC Investment, Nokia, SAP and Teva Pharmaceutical.
Teva Pharmaceutical Industries has just approached Mylan with a public takeover bid valued at $82 per share in cash and stock.
Tuesday's top analyst upgrades and downgrades include Brocade Communications, IAC/InterActiveCorp, Nabors Industries, Priceline, Teva Pharmaceutical and Yamana Gold.
News broke Monday that Teva Pharmaceutical Industries will acquire Auspex Pharmaceuticals. Existing investors will be wondering if they are getting enough in this buyout.
Chris Lange 
